SCHEMBL4598322

SCHEMBL4598322

O=c1c(NCc2cccc(OCCO)c2)c(Nc2ccc3[nH]cnc3c2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.44
ROCK1 Q13464 4/20 0.44
RPS6KB1 P23443 4/20 0.44
GSK3B P49841 3/20 0.44
PRKG1 Q13976 3/20 0.44
CLK4 Q9HAZ1 3/20 0.44
AURKB Q96GD4 3/20 0.44
CHEK1 O14757 2/20 0.44
DAPK3 O43293 2/20 0.44
CHEK2 O96017 2/20 0.44
PRKACA P17612 2/20 0.44
AKT1 P31749 2/20 0.44
AKT2 P31751 2/20 0.44
CLK2 P49760 2/20 0.44
RPS6KA3 P51812 2/20 0.44
PRKAA1 Q13131 2/20 0.44
PRKG2 Q13237 2/20 0.44
PKN2 Q16513 2/20 0.44
CDC42BPA Q5VT25 2/20 0.44
HIPK4 Q8NE63 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4597195 0.90 ROCK2 (0.44) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4906532 0.89 ROCK2 (0.45) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4897991 0.88 RPS6KB1 (0.43) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4908299 0.88 ROCK2 (0.48) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4598466 0.87 GSK3B (0.52) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4599119 0.86 ROCK2 (0.41) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4905587 0.85 ROCK1 (0.48) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4907610 0.84 ROCK1 (0.43) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL14066718 0.83 MAPKAPK2 (0.54) ROCK2ROCK1RPS6KB1GSK3BPRKG1
SCHEMBL4908365 0.83 ROCK2 (0.43) ROCK2ROCK1RPS6KB1GSK3BPRKG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US claimed
EP-1910312-A1 QUADRATIC ACID II DERIVATIVES Merck Patent GmbH (DE) 2008-04-16 EP claimed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO claimed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234266-A1 Squaric Acid Derivatives II CHEK2, CHEK1, SGK3 ROCK2 662/4885ROCK1 713/4885RPS6KB1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.